Changeflow GovPing Healthcare & Life Sciences FDA Orange Book Monthly Additions and Deletions...
Routine Notice Added Final

FDA Orange Book Monthly Additions and Deletions to Prescription and OTC Drug Product Lists

Email

Summary

The FDA Orange Book publishes monthly index files documenting new additions and deletions to its list of approved prescription and OTC drug products, covering January 2021 through March 2026. Products are flagged with symbols indicating additions (>ADD>), deletions (>DLT>), or discontinued marketing status (@). The index is a reference companion to the cumulative Orange Book and its supplements.

“This document is not a cumulative list of approved Prescription and OTC Drug Products but a list of the new additions and new deletions to the Prescription and OTC Drug Product Lists for a specific month.”

FDA , verbatim from source
Published by FDA on fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Orange Book - Approved Drug Products for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 1 changes logged to date.

What changed

The FDA Orange Book now includes monthly index files tracking new additions and deletions to the approved prescription and OTC drug product lists for January 2021 through March 2026. Products are identified using standardized symbols: >ADD> or >A> for additions, >DLT> or >D> for deletions, and @ for discontinued or non-marketed products. This index is informational and must be used alongside the current Cumulative Supplement and main Orange Book.

Affected parties—primarily pharmaceutical companies, healthcare providers, and regulatory affairs professionals—should consult these monthly indexes when verifying the current approval status of specific drug products. The index does not create new compliance obligations but serves as a reference tool for tracking FDA's ongoing changes to the approved drug product landscape.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.


Orange Book Home Page

This document is not a cumulative list of approved Prescription and OTC Drug Products but a list of the new additions and new deletions to the Prescription and OTC Drug Product Lists for a specific month. This information must be used in conjunction with the most current Cumulative Supplement and Orange Book. Additions and deletions are identified in this document by the symbols >ADD> and >DLT>, respectively. Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the current Edition List will then be added to the "Discontinued Drug Product List" of the following Edition.

  • >ADD> or >A> indicates Addition
  • >DLT> or >D> indicates Deletion
  • @ indicates drugs that have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons

2026 Additions and Deletions to Drug Product List

2025 Additions and Deletions to Drug Product List

2024 Additions and Deletions to Drug Product List

2023 Additions and Deletions to Drug Product List

2022 Additions and Deletions to Drug Product List

2021 Additions and Deletions to Drug Product List

2020 Additions and Deletions to Drug Product List

2019 Additions and Deletions to Drug Product List

2018 Additions and Deletions to Drug Product List

2017 Additions and Deletions to Drug Product List

2016 Additions and Deletions to Drug Product List

2015 Additions and Deletions to Drug Product List

2014-2007 Additions and Deletions to Drug Product Lists can be found in the FDA Archive

  • ## Content current as of:

04/10/2026

-

Named provisions

Additions and Deletions to the Drug Product List

Get daily alerts for FDA Orange Book - Approved Drug Products

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug approval tracking Product list maintenance
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Compliance frameworks
GxP
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when FDA Orange Book - Approved Drug Products publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!